The Long Run with Luke Timmerman
Een podcast door Timmerman Report
173 Afleveringen
-
Ep95: Sue Desmond-Hellmann on Becoming a Biotech Leader
Gepubliceerd: 26-7-2021 -
Ep94: Jenny Rooke on Investing in Biotech Tools
Gepubliceerd: 19-7-2021 -
Ep93: Jay Bradner & Andy Plump on Mentoring Young Scientists
Gepubliceerd: 14-6-2021 -
Ep92: Brad Gray on Spatial Biology
Gepubliceerd: 1-6-2021 -
Ep91: Daphne Zohar on Biotech Entrepreneurship
Gepubliceerd: 3-5-2021 -
Ep90: James Sabry on Partnering Amid Scientific Abundance
Gepubliceerd: 19-4-2021 -
Ep89: Emily Leproust on DNA Synthesis at Scale
Gepubliceerd: 29-3-2021 -
Ep88: Amy DuRoss on software and logistics for cell and gene therapy
Gepubliceerd: 15-3-2021 -
Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing
Gepubliceerd: 1-3-2021 -
Ep86: Sek Kathiresan on a Gene-Edited Single Shot for Heart Disease
Gepubliceerd: 9-2-2021 -
Ep85: Luhan Yang on CRISPR Editing for Organ Transplants
Gepubliceerd: 20-1-2021 -
Ep84: Steve Paul on Treatments for Mental Health
Gepubliceerd: 22-12-2020 -
Ep83: David Lee on Impact in Pharmaceuticals
Gepubliceerd: 14-12-2020 -
Ep82: Andrew Farnum on Medicines From Unusual Traits
Gepubliceerd: 23-11-2020 -
Ep81: Simba Gill on Microbiome Therapies
Gepubliceerd: 12-11-2020 -
Ep80: Peter Kolchinsky on Pharma's Soul
Gepubliceerd: 28-10-2020 -
Ep79: Daphne Koller on Machine Learning for Drug Discovery
Gepubliceerd: 26-10-2020 -
Ep78: Pearl Huang on Exoneural Cancer Biology
Gepubliceerd: 13-10-2020 -
Ep77: Jennifer Petter on Drugging RNA Targets
Gepubliceerd: 29-9-2020 -
Ep76: Otello Stampacchia on Becoming a Biotech VC
Gepubliceerd: 8-9-2020
"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
